Hypoxia inducible factor-1 improves the negative functional effects of natriuretic peptide and nitric oxide signaling in hypertrophic cardiac myocytes

Life Sciences

Volumn 87, Issue 1-2, 2010, Pages 9-16

  Tan, Tao ^a   Scholz, Peter M ^a   Weiss, Harvey R ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Cardiac hypertrophy; Cyclic GMP; Cyclic GMP dependent protein kinase; Hypoxic inducible factor 1 (HIF 1); Myocytes; Natriuretic peptides; Nitric oxide

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP DEPENDENT PROTEIN KINASE; DEFEROXAMINE; HYPOXIA INDUCIBLE FACTOR 1; KT 5823; N ACETYL S NITROSOPENICILLAMINE; NATRIURETIC PEPTIDE TYPE C; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA STENOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; FUNCTIONAL DISEASE; HEART CONTRACTION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CARBAZOLES; CARDIOMEGALY; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DEFEROXAMINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; NITRIC OXIDE; S-NITROSO-N-ACETYLPENICILLAMINE; SIGNAL TRANSDUCTION; UP-REGULATION;

MUS;

EID: 77953959103     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2010.05.002     Document Type: Article

References (43)

1. Abassi Z., Karram T., Ellaham S., Winaver J., Hoffman A. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacology & Therapeutics 2004, 102(3):223-241.
2. Belaidi E., Beguin P.C., Levy P., Ribuot C., Godin-Ribuot D. Prevention of HIF-1 activation and iNOS gene targeting by low-dose cadmium results in loss of myocardial hypoxic preconditioning in the rat. American Journal of Physiology - Heart and Circulatory physiology 2008, 294(2):H901-H908.
3. Cai Z., Manalo D.J., Wei G., Rodriguez E.R., Fox-Talbot K., Lu H., Zweier J.L., Semenza G.L. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003, 108(1):79-85.
4. Carabelli V., D'Ascenzo M., Carbone E., Grassi C. Nitric oxide inhibits neuroendocrine Ca(V)1L-channel gating via cGMP-dependent protein kinase in cell-attached patches of bovine chromaffin cells. Journal of Physiology 2002, 541(Pt 2):351-366.
5. Carreno J.E., Apablaza F., Ocaranza M.P., Jalil J.E. Cardiac hypertrophy: molecular and cellular events. Revista Española de Cardiología 2006, 59(5):473-486.
6. Chi O.Z., Hunter C., Liu X., Weiss H.R. Effects of deferoxamine on blood-brain barrier disruption and VEGF in focal cerebral ischemia. Neurological Research 2008, 30(3):288-293.
7. Dery M.A., Michaud M.D., Richard D.E. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. The International Journal of Biochemistry & Cell Biology 2005, 37(3):535-540.
8. Hagen T., Taylor C.T., Lam F., Moncada S. Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha. Science 2003, 302(5652):1975-1978.
9. Huang L.E., Willmore W.G., Gu J., Goldberg M.A., Bunn H.F. Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling. Journal of Biological Chemistry 1999, 274(13):9038-9044.
10. Jiang Y., Reynolds C., Xiao C., Feng W., Zhou Z., Rodriguez W., Tyagi S.C., Eaton J.W., Saari J.T., Kang Y.J. Dietary copper supplementation reverses hypertrophic cardiomyopathy induced by chronic pressure overload in mice. The Journal of Experimental Medicine 2007, 204(3):657-666.
11. Katz E., Zhang Q., Weiss H.R., Scholz P.M. T4-induced cardiac hypertrophy disrupts cyclic GMP mediated responses to brain natriuretic peptide in rabbit myocardium. Peptides 2006, 27(9):2276-2283.
12. Kim C.H., Cho Y.S., Chun Y.S., Park J.W., Kim M.S. Early expression of myocardial HIF-1alpha in response to mechanical stresses: regulation by stretch-activated channels and the phosphatidylinositol 3-kinase signaling pathway. Circulation Research 2002, 90(2):E25-E33.
13. Kimura H., Ogura T., Kurashima Y., Weisz A., Esumi H. Effects of nitric oxide donors on vascular endothelial growth factor gene induction. Biochemical and Biophysical Research Communications 2002, 296(4):976-982.
14. Kojda G., Kottenberg K. Regulation of basal myocardial function by NO. Cardiovascular Research 1999, 41(3):514-523.
15. Lefer D.J. Induction of HIF-1alpha and iNOS with siRNA: a novel mechanism for myocardial protection. Circulation Research 2006, 98(1):10-11.
16. Lewis G.D., Semigran M.J. Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension. Current Heart Failure Reports 2004, 1(4):183-189.
17. London B. Natriuretic peptides and cardiac hypertrophy. Journal of the American College of Cardiology 2006, 48(3):506-507.
18. Lucas K.A., Pitari G.M., Kazerounian S., Ruiz-Stewart I., Park J., Schulz S., Chepenik K.P., Waldman S.A. Guanylyl cyclases and signaling by cyclic GMP. Pharmacology Reviews 2000, 52(3):375-414.
19. Luciano J.A., Tan T., Zhang Q., Huang E., Scholz P., Weiss H.R. Hypoxia inducible factor-1 improves the actions of nitric oxide and natriuretic peptides after simulated ischemia-reperfusion. Cellular Physiology & Biochemistry 2008, 21(5-6):421-428.
20. Meyer M., Zhang Q., Khurana K., Scholz P.M., Weiss H.R. Negative functional effects of natriuretic peptides are attenuated in hypertrophic cardiac myocytes by reduced particulate guanylyl cyclase activity. Journal of Cardiovascular Pharmacology 2007, 49(2):100-105.
21. Moalem J., Davidov T., Zhang Q., Grover G.J., Weiss H.R., Scholz P.M. Negative inotropic effects of C-type natriuretic peptide are attenuated in hypertrophied ventricular myocytes associated with reduced cyclic GMP production. Journal of Surgical Research 2006, 135(1):38-44.
22. Moalem J., Weiss H.R., Davidov T., Rodriguez R., Molino B., Lazar M.J., Scholz P.M. Heart failure reduces both the effects and interaction between cyclic GMP and cyclic AMP. Journal of Surgical Research 2006, 134(2):300-306.
23. Poellinger L., Johnson R.S. HIF-1 and hypoxic response: the plot thickens. Current Opinions in Genetics & Development 2004, 14(1):81-85.
24. Rame J.E., Dries D.L. Heart failure and cardiac hypertrophy. Current Treatment Options in Cardiovascular Medicine 2007, 9(4):289-301.
25. Rastaldo R., Pagliaro P., Cappello S., Penna C., Mancardi D., Westerhof N., Losano G. Nitric oxide and cardiac function. Life Sciences 2007, 81(10):779-793.
26. Sandau K.B., Zhou J., Kietzmann T., Brune B. Regulation of the hypoxia-inducible factor 1alpha by the inflammatory mediators nitric oxide and tumor necrosis factor-alpha in contrast to desferroxamine and phenylarsine oxide. Journal of Biological Chemistry 2001, 276(43):39805-39811.
27. Sano M., Minamino T., Toko H., Miyauchi H., Orimo M., Qin Y., Akazawa H., Tateno K., Kayama Y., Harada M., Shimizu I., Asahara T., Hamada H., Tomita S., Molkentin J.D., Zou Y., Komuro I. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007, 446(7134):444-448.
28. Schlossmann J., Ammendola A., Ashman K., Zong X., Huber A., Neubauer G., Wang G.X., Allescher H.D., Korth M., Wilm M., Hofmann F., Ruth P. Regulation of intracellular calcium by a signalling complex of IRAG, IP3 receptor and cGMP kinase Ibeta. Nature 2000, 404(6774):197-201.
29. 2+ channel regulation by cGMP-dependent protein kinase type I in adult cardiomyocytes from PKG I transgenic mice. Cardiovascular Research 2003, 60(2):268-277.
30. Semenza G.L. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. Journal of Applied Physiology 2000, 88(4):1474-1480.
31. Semenza G.L. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends in Molecular Medicine 2001, 7(8):345-350.
32. 2-regulated gene expression: transcriptional control of cardiorespiratory physiology by HIF-1. Journal of Applied Physiology 2004, 96(3):1173-1177. discussion 1170-1172.
33. Shyu K.G., Liou J.Y., Wang B.W., Fang W.J., Chang H. Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. Journal of Biomedical Science 2005, 12(2):409-420.
34. Su J., Zhang Q., Moalem J., Tse J., Scholz P.M., Weiss H.R. Functional effects of C-type natriuretic peptide and nitric oxide are attenuated in hypertrophic myocytes from pressure-overloaded mouse hearts. American Journal of Physiology - Heart and Circulatory physiology 2005, 288(3):H1367-H1373.
35. Sun Y., Carretero O.A., Xu J., Rhaleb N.E., Wang F., Lin C., Yang J.J., Pagano P.J., Yang X.P. Lack of inducible NO synthase reduces oxidative stress and enhances cardiac response to isoproterenol in mice with deoxycorticosterone acetate-salt hypertension. Hypertension 2005, 46(6):1355-1361.
36. Sun Y., Carretero O.A., Xu J., Rhaleb N.E., Yang J.J., Pagano P.J., Yang X.P. Deletion of inducible nitric oxide synthase provides cardioprotection in mice with 2-kidney, 1-clip hypertension. Hypertension 2009, 53(1):49-56.
37. Weidemann A., Klanke B., Wagner M., Volk T., Willam C., Wiesener M.S., Eckardt K.U., Warnecke C. Hypoxia, via stabilization of the hypoxia-inducible factor HIF-1alpha, is a direct and sufficient stimulus for brain-type natriuretic peptide induction. Biochemical Journal 2008, 409(1):233-242.
38. Wilhide M.E., Jones W.K. Potential therapeutic gene for the treatment of ischemic disease: Ad2/hypoxia-inducible factor-1alpha (HIF-1)/VP16 enhances B-type natriuretic peptide gene expression via a HIF-1-responsive element. Molecular Pharmacology 2006, 69(6):1773-1778.
39. Zaccolo M., Movsesian M.A. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circulation Research 2007, 100(11):1569-1578.
40. Zhang Q., Lazar M., Molino B., Rodriguez R., Davidov T., Su J., Tse J., Weiss H.R., Scholz P.M. Reduction in interaction between cGMP and cAMP in dog ventricular myocytes with hypertrophic failure. American Journal of Physiology - Heart and Circulatory physiology 2005, 289(3):H1251-H1257.
41. Zhang Q., Scholz P.M., Pilzak A., Su J., Weiss H.R. Role of phospholamban in cyclic GMP mediated signaling in cardiac myocytes. Cellular Physiology & Biochemistry 2007, 20(1-4):157-166.
42. Zhou J., Brune B. Cytokines and hormones in the regulation of hypoxia inducible factor-1alpha (HIF-1alpha). Cardiovascular Hematological Agents in Medicinal Chemistry 2006, 4(3):189-197.
43. Zhu H., Cai C., Chen J. Suppression of P-glycoprotein gene expression in Hs578T/Dox by the overexpression of caveolin-1. FEBS Letters 2004, 576(3):369-374.